Comparison of Two Doses of Intranasal Dexmedetomidine as Premedication in Children

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2010 by The University of Hong Kong.
Recruitment status was  Recruiting
Information provided by:
The University of Hong Kong Identifier:
First received: February 7, 2010
Last updated: February 8, 2010
Last verified: February 2010
Intranasal dexmedetomidine has shown to be an effective sedative when used prior to anaesthetic induction as premedication. 1mcg/kg intranasal dexmedetomidine was used in previous study and it produced satisfactory sedation in more than 50% of the children at the time of anaesthetic induction with no adverse effect. In this study we aim to compare 1mcg/kg with 2mcg/kg intranasal dexmedetomidine in children. We expect more children would attain satisfactory sedation prior to anaesthetic induction when higher dose is used.

Condition Intervention Phase
Patient Between 1-8 Years Old Undergoing Elective Surgery at Queen Mary Hospital
Drug: Dexmedetomidine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of Two Doses of Intranasal Dexmedetomidine as Premedication in Children - a Double-blinded Randomized Controlled Trial

Resource links provided by NLM:

Further study details as provided by The University of Hong Kong:

Primary Outcome Measures:
  • proportion of children attained satisfactory sedation [ Time Frame: one hour ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • time to onset of sedation [ Time Frame: one hour ] [ Designated as safety issue: No ]

Estimated Enrollment: 104
Study Start Date: July 2009
Estimated Study Completion Date: June 2010
Estimated Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1mcg/kg
1mcg/kg intranasal dexmedetomidine administered 45 minutes befoe anesthesia induction
Drug: Dexmedetomidine
Intranasal dexmedetomidine is given as premedication prior to induction of anesthesia
Active Comparator: 2mcg/kg
2mcg/kg intranasal dexmedetomidine given 45 minutes prior to anesthetic induction
Drug: Dexmedetomidine
Intranasal dexmedetomidine is given as premedication prior to induction of anesthesia


Ages Eligible for Study:   1 Year to 8 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 1-12 years old
  • American Society of Anesthesiologists (ASA) 1-2
  • Elective surgery
  • Children with autism or pervasive personality disorder

Exclusion Criteria:

  • American Society of Anaesthesiologists (ASA) 3-5
  • Allergy or hypersensitive reaction to dexmedetomidine
  • Known cardiac arrhythmia or congenital heart disease
  • Mentally disabled
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01065701

Contact: Vivian M Yuen, MBBS 853 93034274

Hong Kong
QUeen Mary Hospital Recruiting
Hong Kong, Hong Kong
Principal Investigator: Vivian M Yuen, MBBS         
Sponsors and Collaborators
The University of Hong Kong
Principal Investigator: Vivian M Yuen, MBBS Associate Consultant, Queen Mary Hospital
  More Information

Responsible Party: Dr. Vivian Man-ying YUEN, Queen Mary Hospital Identifier: NCT01065701     History of Changes
Other Study ID Numbers: InDex3 
Study First Received: February 7, 2010
Last Updated: February 8, 2010
Health Authority: Hong Kong: Ethics Committee

Additional relevant MeSH terms:
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Analgesics, Non-Narcotic
Central Nervous System Depressants
Hypnotics and Sedatives
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Sensory System Agents processed this record on May 22, 2016